The target audience for this activity is pharmacists—including specialty, managed care, and clinical pharmacists—who care for patients with CLL/SLL, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.
The goal of this activity is to improve the knowledge, competence, and confidence of learners in the optimal treatment and associated therapies for CLL/SLL.
Upon completion of this activity, participants should be able to:
Apply evidence, guidelines, and best practices to optimally integrate targeted drug classes in treatment-naive or relapsed/refractory CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens
Compare the differences in selectivity, binding, efficacy, and adverse event profiles of agents with a similar molecular target used to treat CLL/SLL
Evaluate the role of measurable residual disease, novel combinations, and CAR T-cell therapy in CLL/SLL
Manage adverse events associated with the use of targeted agents, including single-agent and combination approaches
Determine the role of specialty and managed care pharmacists in the interprofessional collaborative care team to support evidence-based, equitable care that improves patient outcomes
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Karen M. Fancher, PharmD, BCOP
Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Clinical Pharmacy Specialist, Oncology
University of Pittsburgh Medical Center Passavant
Karen M. Fancher, PharmD, BCOP: consultant/advisor/speaker: AstraZeneca, BTG Specialty Pharmaceuticals, G1 Therapeutics.
Emily Hollinghurst, PharmD, BCOP, CSP, APh
Department of Pharmacy Practice
Loma Linda University, School of Pharmacy
Clinical Pharmacy Specialist
Specialty Pharmacy Services
Loma Linda University Medical Center
Loma Linda, California
Emily Hollinghurst, PharmD, BCOP, CSP, APh: consultant/advisor/speaker: Eisai.
The planners and content peer reviewers from ProCE, LLC and Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-23-013-H01-P has been assigned to this home study application-based activity. This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65 or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.